Consolidated Planning Corp Raises Stake in Merck & Co., Inc. (NYSE:MRK)

Consolidated Planning Corp raised its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 4.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,640 shares of the company’s stock after purchasing an additional 1,794 shares during the period. Consolidated Planning Corp’s holdings in Merck & Co., Inc. were worth $5,890,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Vermillion & White Wealth Management Group LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Burkett Financial Services LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Bare Financial Services Inc acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Rakuten Securities Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $30,000. Finally, RIA Advisory Group LLC purchased a new position in Merck & Co., Inc. during the 4th quarter worth approximately $30,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on MRK shares. Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 27th. Berenberg Bank raised their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a report on Monday, March 11th. Truist Financial raised their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Argus raised Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Get Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

NYSE:MRK traded down $1.61 during trading hours on Tuesday, hitting $124.17. The company’s stock had a trading volume of 741,589 shares, compared to its average volume of 8,411,446. The company has a market capitalization of $314.50 billion, a PE ratio of 139.73, a PEG ratio of 2.44 and a beta of 0.38. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63. The business’s 50-day moving average is $129.05 and its two-hundred day moving average is $125.26. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.40 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, July 8th. Investors of record on Monday, June 17th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with's FREE daily email newsletter.